Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dermatopontin (DPT) is a small, non-collagenous, tyrosine-rich acidic protein found in the extracellular matrix, particularly abundant in the dermis. It mediates cell adhesion through binding to cell surface integrins, enhances the biological activity of transforming growth factor beta 1 (TGF-β1), and regulates extracellular matrix (ECM) architecture by accelerating collagen and fibronectin fibrillogenesis. DPT is implicated in tissue repair processes, including wound healing, by promoting keratinocyte migration and acting as a communication link between dermal fibroblasts and the matrix. Loss of DPT function results in ECM abnormalities reminiscent of Ehlers-Danlos syndrome in animal models. While DPT influences several biological functions in the ECM, it is not classified as a receptor, enzyme, transporter, or other classical drug target family and currently no drugs are known to target it directly. Its altered expression is noted in certain disease states, such as carcinomas, fibrosis, and connective tissue disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dermatopontin (DPT).